🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsCompounded sema dosing calculator — 12 month update

Compounded sema dosing calculator — 12 month update

CarlaRPh_TPA Sun, Mar 15, 2026 at 12:53 PM 27 replies 1,129 viewsPage 1 of 6
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Mar 15, 2026 at 12:53 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The bit I cannot resolve on my own is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Numbers rather than impressions, if you have them.

21 16FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 18 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Mar 15, 2026 at 1:59 PM#2

Answering the narrow version, because the broad one does not have a single answer. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

20 15AmyNC_wife, SkepticalSean, Dr.CardioMD and 17 others
Reply Quote Save Share Report
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Mar 15, 2026 at 3:05 PM#3
RetaRick_CA said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreeing with RetaRick_CA, and the qualification matters more than the agreement. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

19 14kim_atl_prep, sarah_TO, wendy_avl and 16 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Mar 15, 2026 at 4:11 PM#4
CarlaRPh_TPA said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Same position here, arrived at the long way round. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

18 13DeniseRN_TPA, SandraNC_45, Dr.EndoIndy and 15 others
Reply Quote Save Share Report
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
Mar 15, 2026 at 10:27 PM#5

From the other side of the consultation, briefly.

FDA inspection results for compounding pharmacies selling compounded supply: you can look up any 503B facility's FDA inspection history on the FDA website.

Check for: Form 483 observations (violations), warning letters, and recall history. A clean inspection record is a strong indicator of quality. My pharmacy has had 1 Form 483 observations in their last 2 inspections.

This is public information. Use it. Link: fda.gov/inspections-compliance-enforcement-and-criminal-investigations

Last edited: Mar 16, 2026 at 3:27 AM
17 12MikeNYC_runner and 14 others
Reply Quote Save Share Report
1236

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register